IA
TVTX icon

IPL Advisers’s Travere Therapeutics TVTX Stock Holding History

IPL Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$5.29M Hold
251,045
– – 3.35% 12
2017
Q3 		$6.25M Hold
251,045
– – 2.56% 16
2017
Q2 		$4.87M Hold
251,045
– – 1.92% 14
2017
Q1 		$4.63M Buy
+251,045
New +$4.91M 1.99% 16

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

IPL Advisers's TVTX Position: Q4 2017 in Review

IPL Advisers held its Travere Therapeutics (TVTX) position steady in Q4 2017 at 251,045 shares worth $5.29M. The position accounts for 3.35% of the portfolio, ranked #12.

IPL Advisers first reported a position in TVTX in Q1 2017 and has held it in 4 quarters since. The position peaked at $6.25M in Q3 2017. 120 funds tracked by Wall St. Rank hold TVTX as of Q4 2017.

  • IPL Advisers held 251,045 shares of Travere Therapeutics worth $5.29M as of Q4 2017.
  • IPL Advisers left its Travere Therapeutics share count unchanged in Q4 2017.
  • Travere Therapeutics made up 3.35% of IPL Advisers's portfolio in Q4 2017, its #12 holding.
  • IPL Advisers first reported a position in Travere Therapeutics in Q1 2017 and has held it in 4 quarters since.
  • IPL Advisers's Travere Therapeutics position peaked at $6.25M in Q3 2017.
  • 120 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2017.

Based on IPL Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.